---

Assessment of efficacy and safety of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion

---

Original Article

Author Details : Neepa Gohil, Kaumudi K Shinde*, Yash Solanki

Volume : 7, Issue : 2, Year : 2021

Article Page : 376-380

https://doi.org/10.18231/j.ijceo.2021.074

Suggest article by email

Get Permission

---

Abstract

Background: The aim of the study was to assess the efficacy and safety of individualized repeated injection of intravitreal anti-VEGF ranibizumab for preserving or improving vision (BCVA) and central foveal thickness (CFT) in macular edema secondary to retinal vein occlusion (RVO).
Materials and Methods: 25 eyes of 25 patients with RVO were included. General and systemic examination was done. IOP measurement, slit lamp, fundus examination, BCVA assessment and OCT was done. CFT was measured to assess macular edema. Injection intravitreal ranibizumab (0.5mg/0.05ml) was given in the affected eye, every 6 weeks, till week 18, if CFT>250 µm. Total 3 injections were given in each patient. Final follow-up visit was at week 36.
Results: Hypertension (72%), DM (20%) and altered lipid profile (16%) were associated comorbidities. There was significant reduction in mean CFT from baseline visit (516.08±35.21) to week 18 visit (203.32±4.97) with P<0 P=0.44).> There was significant improvement in mean BCVA from baseline visit (0.87±0.03) to week 18 visit (0.27±0.03). There was no significant statistical difference between week 18 BCVA and week 36 BCVA (P=0.76). There was a significant reduction in mean BCVA from baseline visit (0.87±0.03) to week 36(0.35±0.05) with P<0> Conclustion: Individualized repeated intravitreal injection of ranibizumab showed improvement in BCVA and CFT in patients with macular edema secondary to RVO. For long term maintenance, control of systemic comorbidities is essential.

Keywords: Intravitreal ranibizumab, Macular edema, Retinal vein occlusion.

How to cite : Gohil N, Shinde K K, Solanki Y, Assessment of efficacy and safety of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion. Indian J Clin Exp Ophthalmol 2021;7(2):376-380

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.